Intensity Therapeutics (INTS) Treasury Shares (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Treasury Shares came in at $338098.0 in Q1 2026, down 83.44% YoY from $2.0 million in Q1 2025, and little changed on a QoQ basis from $339298.0 in Q4 2025.
Intensity Therapeutics (INTS) Treasury Shares (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Treasury Shares data on file, last reported at $338098.0 in Q1 2026.
- Quarterly Treasury Shares fell 83.44% year-over-year to $338098.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $338098.0 (down 83.44% YoY) and the FY2025 annual result came in at $339298.0, up 315.49% from the prior year.
- Treasury Shares steadied at $338098.0 in Q1 2026, from $339298.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $8.6 million in Q2 2025 to a low of $81663.0 in Q4 2024.
- A 5-year average of $3.2 million and a median of $1.4 million in 2024 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2024 — Treasury Shares sank 89.82% — and 2025, when it soared 936.02%.
- Tracing INTS's Treasury Shares over 5 years: stood at $5.0 million in 2022, then slumped by 83.96% to $801950.0 in 2023, then slumped by 89.82% to $81663.0 in 2024, then jumped by 315.49% to $339298.0 in 2025, then declined by 0.35% to $338098.0 in 2026.
- The last three Treasury Shares figures came in at $338098.0 (Q1 2026), $339298.0 (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.72 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 8.96 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 335,658.00 |
| Jun 30, 2026 | 335,658.00 |
| Mar 31, 2026 | 338,098.00 |
| Mar 31, 2026 | 338,098.00 |
| Dec 31, 2025 | 339,298.00 |
| Dec 31, 2025 | 339,298.00 |
| Sep 30, 2025 | 8.59 Mn |
| Sep 30, 2025 | 8.59 Mn |
| Jun 30, 2025 | 8.64 Mn |
| Jun 30, 2025 | 8.64 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 81,663.00 |
| Dec 31, 2024 | 81,663.00 |
| Sep 30, 2024 | 829,450.00 |
| Sep 30, 2024 | 829,450.00 |
| Dec 31, 2023 | 801,950.00 |
| Dec 31, 2023 | 801,950.00 |
| Mar 31, 2023 | 5.00 Mn |
| Mar 31, 2023 | 5.00 Mn |